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Abstract
Background: The association of Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) common variants (rs4402960
and rs1470579) with type 2 diabetes (T2D) has been performed in different populations. The aim of this study was to
evaluate the association of alternative variants of IGF2BP2; rs6777038, rs16860234 and rs7651090 with glutamic acid
decarboxylase antibodies (GADA) negative diabetes in Malaysian Subjects.
Methods/Principal Findings: IGF2BP2; rs6777038, rs16860234 and rs7651090 single nucleotide polymorphisms (SNPs) were
genotyped in 1107 GADA negative diabetic patients and 620 control subjects of Asian from Malaysia. The additive genetic
model adjusted for age, race, gender and BMI showed that alternative variants; rs6777038, rs16860234 and rs7651090 of
IGF2BP2 associated with GADA negative diabetes (OR= 1.21; 1.36; 1.35, P = 0.03; 0.0004; 0.0002, respectively). In addition,
the CCG haplotype and diplotype CCG-TCG increased the risk of diabetes (OR= 1.51, P = 0.01; OR= 2.36, P = 0.009,
respectively).
Conclusions/Significance: IGF2BP2 alternative variants were associated with GADA negative diabetes. The IGF2BP2
haplotypes and diplotypes increased the risk of diabetes in Malaysian subject.
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Introduction
Diabetes mellitus is a quickly emergent public health problem
with a tremendous impact on morbidity and premature mortality
worldwide. It is a complicated heterogeneous metabolic disorder
that affects 366 million people worldwide (6.4% of the world’s
adult population aged between 20–79 years). This number will be
increased to 552 million by 2030 [1]. More than 2.03 million of
Malaysians have diabetes mellitus (11.66% of the Malaysian’s
adult population) [1]. Among T2D patients, Latent Autoimmune
Diabetes of Adults (LADA) occurs in 2.8–22.3% of individuals
[2,3,4]. LADA can be distinguished with evidence of GADA
positivity in adult diabetic patients who clinically resemble T2D at
diagnosis [2,5,6] and do not initially require insulin for at least 6
months [7].
It is widely accepted that interactions between multiple
environmental and genetic factors contribute to the initiation
and progression of T2D [8,9,10]. Several genes those are
associated with T2D in more than one population. However,
subsequent association studies showed some variants that were
highly associated with T2D in one group of subjects were not
associated in other. GWA studies on Caucasians revealed that
IGF2BP2 is a candidate risk gene for T2D
[11,12,13,14,15,16,17,18].
The majority of subsequent association studies of IGF2BP2 with
T2D were focused on intron 2 SNPs; rs4402960 and rs1470579
[10,13,19,20,21,22,23,24,25,26,27,28,29]. It is becoming clear
that single susceptibility locus is not shared among all ethnic
groups. In addition, haplotype variation in populations may
indicate different SNPs within IGF22BP2 gene that may be
associated with T2D, which might be located at a distance
downstream or upstream of the most common variants. However,
there are limited studies on the association of IGF2BP2 alternative
variant; rs6777038, rs16860234 and rs7651090. The aim of this
study was to evaluate the association of alternative variations




This study was approved by the local Medical Ethics
Committee of University Malaya Medical Centre. Written
informed consent was obtained from each participant.
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Subjects and Data Collection
Case-control study was conducted at the University Malaya
Medical Centre (UMMC) Kuala Lumpur. The patients previously
diagnosed with T2D who attended the UMMC for treatment were
invited to participate in this study (case group). For the control
group, subjects who were enrolled for health check-up at UMMC
were approached to participate in this study. All participants
enrolled in this study were Malaysian aged 30–70 years in which
non-probability sampling was used. Venus blood (10ml) was
collected from each participant after obtaining the consent form.
WinPepi program was used to calculate the sample size for control
and case group based on multiple logistic regression at significant
level of 0.05, and 85% power to detect a week association (multiple
correlation coefficient, 0.25). The maximum number was for the
recessive genotypes of rs16860234 (582 subjects in each group).
Demographic and Biochemical Analysis
Fasting plasma glucose (FPG), high density lipoprotein choles-
terol (HDLc), and triglycerides (TG) were measured by an
automated analyzer DimensionH RxL MaxH Integrated Chemistry
System (Siemens Healthcare Diagnostics Inc., Deerfield, IL USA).
Fasting plasma insulin (FPI) was measured by ADVIA Centaur
assay XP Immunoassay System (Siemens Healthcare Diagnostics
Inc. Deerfield, IL USA). Normal and pathological controls were
included with each run of biochemical analysis. GADA were
analyzed by ELISA kit RSR GAD65 autoantibody (GAD Ab)
(RSR Limited, Cardiff, UK). The analysis was done manually
according to the manufacturer’s protocol. Plates were read at
450 nm using a microplate reader (BioRad, Calabasas, USA).
GADA Positive and negative controls were included with each
run. Blood pressure (BP) and waist parameter were measured
using standardized protocols. HOMA-b (a measure of b-cell
function) and HOMA-IR (a measure of insulin resistance) were
calculated using the Homeostasis Model Assessment (HOMA2)
Calculator v2.2, which is available online from Oxford Center for
Diabetes, Endocrinology and Metabolism.
SNPs Selection and Genotyping
IGF2BP2 alternative variant; rs6777038, rs16860234 and
rs7651090 were selected based on [28,30] studies. The
rs7651090 is a tag SNP which is highly linked with the most
common IGF2BP2 variants SNPs rs4402960 and rs1470579 [31].
The rs6777038 and rs16860234 are tag SNPs for haplotype blocks
among Asians. Genomic DNA was isolated from peripheral blood
leukocytes by using a commercially WizardH Genomic DNA
Purification Kit (Promega Corporation, Madison, WI, USA)
according to the manufacturer’s protocol. The IGF2BP2 SNPs
(rs6777038, rs16860234 and rs7651090) were genotyped by pre-
design Taqman genotype assay (Applied Biosystems Inc, Foster
City, USA) according to the manufacturer’s protocol using the
StepOnePlus Real-Time PCR system (Applied Biosystems Inc,
Foster City, USA). The call rates for genotyping were more than
98.5%. To ensure the accuracy, 10% of the samples were re-
genotyped; the SNPs genotypes were 100% concordant. No
template controls (NTC) were included in each run of real time
PCR, which indicated there was no DNA contamination.
Statistical Analysis
Demographic and biochemical parameters were log-trans-
formed before statistical analyses and then re-transformed back
and presented as geometric means. Hardy–Weinberg equilibrium
analyses were performed with DeFinetti program (http://ihg.gsf.
de/cgi-bin/hw/hwa1.pl) (Institute of Human Genetics). SNP &
Variation Suite v7.x (Golden Helix, Bozeman, MT, USA) was
used to study the linkage disequilibrium (LD) between SNPs and
construct haplotypes and diplotypes of related SNPs. The
Table 1. Association of IGF2BP2 polymorphism with GADA negative diabetes among Malaysian subjects and ethnic groups.
IGF2BP2 SNPs Control GADA negative diabetes Recessive Dominant Additive
OR (95% CI)
Freq. 11/12/22 Freq. 11/12/22 P-Value
rs6777038 (C,T)
Combined* 0.29 305/258/47 0.33 479/517/104 1.25(0.85–1.85) 0.25 1.27(1.02–1.58) 0.03 1.21(1.02–1.44) 0.03
Malay# 0.28 132/99/20 0.30 202/187/34 0.83(0.44–1.55) 0.55 1.08(0.76–1.54) 0.67 1.01(0.76–1.32) 0.97
Chinese# 0.21 123/74/5 0.27 148/129/13 2.39(0.76–7.54) 0.14 1.75(1.16–2.62) 0.007 1.69(1.18–2.42) 0.004
Indian# 0.41 50/85/22 0.41 129/201/57 1.15(0.66–2.00) 0.61 0.97(0.65–1.47) 0.89 1.04(0.78–1.38) 0.80
rs16860234 (A,C)
Combined* 0.24 356/210/41 0.30 559/414/124 2.06(1.36–3.12) 0.001 1.35(1.09–1.69) 0.01 1.36(1.14–1.61) 0.0004
Malay# 0.22 153/85/12 0.28 224/160/37 2.55(1.19–5.48) 0.02 1.40(0.98–2.01) 0.07 1.43(1.07–1.91) 0.01
Chinese# 0.18 138/53/9 0.24 182/77/30 3.12(1.30–7.49) 0.01 1.41(0.92–2.16) 0.11 1.47(1.05–2.05) 0.02
Indian# 0.36 65/72/20 0.38 153/177/57 1.26(0.71–2.25) 0.43 1.12(0.76–1.65) 0.57 1.12(0.85–1.49) 0.42
rs7651090 (A,G)
Combined* 0.32 292/249/67 0.38 452/462/183 1.82(1.30–2.53) 0.0004 1.38(1.11–1.71) 0.004 1.35(1.16–1.58) 0.0002
Malay# 0.31 119/107/25 0.35 181/184/55 1.46(0.84–2.56) 0.18 1.39(0.97–1.99) 0.07 1.30(0.99–1.69) 0.06
Chinese# 0.22 123/68/9 0.26 166/98/25 2.46(1.07–5.64) 0.03 1.34(0.89–2.02) 0.15 1.39(1.01–1.92) 0.046
Indian# 0.45 50/74/33 0.50 105/180/103 1.56(0.97–2.50) 0.07 1.30(0.86–1.97) 0.22 1.29(0.99–1.69) 0.06
Risk allele is denoted in boldface. *Controlled for age, race, gender and BMI. #Controlled for age, gender and BMI. The outliers (studentized residual is greater than 2.0
or less than 22.0) were excluded Freq., risk allele frequency. 11, homozygous of major allele; 12, heterozygous; 22, homozygous of minor allele. GADA, glutamic acid
decarboxylase antibodies.
doi:10.1371/journal.pone.0045573.t001
IGF2BP2 Alternative Variants and GADA Negative T2D
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Figure 1. Pairwise linkage disequilibrium among IGF2BP2 SNPs in Malaysian subjects.
doi:10.1371/journal.pone.0045573.g001
Table 2. Association of common haplotypes and diplotypes with GADA negative diabetes among Malaysian subjects.
rs6777038,
rs16860234, rs7651090 Frequency P-Value OR (95% CI)
Control GADA negative diabetes
Haplotypes
TCG 0.26 0.30 0.11 1.22(0.96–1.55)
CAA 0.34 0.26 0.001 0.67(0.53–0.84)
CCG 0.13 0.17 0.01 1.51(1.10–2.06)
TAA 0.11 0.13 0.29 1.20(0.86–1.67)
TAG 0.10 0.09 0.92 0.98(0.68–1.41)
CAG 0.03 0.03 0.60 1.20(0.61–2.35)
Diplotypes
CAA-CAA 0.34 0.26 0.001 0.67(0.53–0.84)
CAA-TCG 0.17 0.17 0.54 0.92(0.69–1.21)
CAA-TAA 0.10 0.12 0.36 1.17(0.84–1.64)
CAA-CCG 0.09 0.10 0.20 1.27(0.88–1.85)
CAA-TAG 0.08 0.07 0.70 0.93(0.62–1.38)
CCG-TCG 0.03 0.04 0.009 2.36(1.24–4.47)
Controlled for age, gender, race and BMI. The outliers (studentized residual is greater than 2.0 or less than 22.0) were excluded. GADA, glutamic acid decarboxylase
antibodies.
doi:10.1371/journal.pone.0045573.t002
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statistical analyses were conducted using Social Package of
Statistical Science (SPSS) 11.5 (LEAD Technologies; Inc. USA).
Associations of IGF2BP SNPs, recessive, dominant and additive
genetic models, haplotypes and diplotypes with T2D were
evaluated by logistic regression controlled for age, gender and
body mass index. The significance level was considered P,0.05.
Results
A total of 1140 patients with T2D and 973 non-diabetic control
subjects were included in this study. The GADA analysis on the
diabetics revealed 33 GADA positive diabetic patients; (LADA
patients) thus; they were excluded from further analysis. Applica-
tion of the new metabolic syndrome (MetS) criteria [32] on non-
diabetic control subjects showed 353 subjects had metabolic
Table 3. Association of common haplotypes and diplotypes with GADA negative diabetes among Malaysian races.
rs6777038, rs16860234,
rs7651090 Control GADA negative diabetes
Malay (n=254) Chinese (n =204) Indian (n =162) Malay (n =425) Chinese (n=293) Indian (n=389)
Haplotypes
TCG Freq. 0.22 0.17 0.42 0.27 0.22 0.39
OR (95% CI) 1.23(0.81–1.87) 1.62(0.98–2.69) 0.91(0.62–1.34)
P-Value 0.32 0.06 0.65
CAA Freq. 0.35 0.44 0.20 0.28 0.37 0.16
OR (95% CI) 0.65(0.45–0.95) 0.67(0.45–1.01) 0.72(0.44–1.18)
P-Value 0.028 0.06 0.19
CCG Freq. 0.15 0.10 0.12 0.18 0.11 0.20
OR (95% CI) 1.49(0.92–2.43) 0.93(0.49–1.78) 2.08(1.16–3.72)
P-Value 0.11 0.83 0.01
TAA Freq. 0.10 0.13 0.09 0.13 0.16 0.11
OR (95% CI) 1.21(0.70–2.10) 1.25(0.72–2.18) 1.18(0.62–2.26)
P-Value 0.49 0.43 0.62
TAG Freq. 0.11 0.07 0.10 0.09 0.08 0.10
OR (95% CI) 0.86(0.49–1.51) 1.31(0.60–2.85) 1.07(0.57–2.02)
P-Value 0.59 0.50 0.84
CAG Freq. 0.03 0.03 0.02 0.03 0.02 0.03
OR (95% CI) 2.28(0.74–7.05) 0.58(0.18–1.87) 1.53(0.41–5.65)
P-Value 0.15 0.36 0.53
Diplotypes
CAA-CAA Freq. 0.35 0.44 0.20 0.28 0.37 0.16
OR (95% CI) 0.65(0.45–0.95) 0.67(0.45–1.01) 0.72(0.44–1.18)
P-Value 0.028 0.06 0.19
CAA-TCG Freq. 0.14 0.13 0.28 0.16 0.13 0.21
OR (95% CI) 0.99(0.60–1.61) 1.09(0.61–1.94) 0.69(0.45–1.07)
P-Value 0.96 0.78 0.10
CAA-TAA Freq. 0.10 0.12 0.08 0.12 0.15 0.10
OR (95% CI) 1.17(0.67–2.02) 1.16(0.66–2.04) 1.24(0.64–2.42)
P-Value 0.59 0.60 0.53
CAA-CCG Freq. 0.11 0.08 0.06 0.14 0.04 0.11
OR (95% CI) 1.65(0.95–2.87) 0.49(0.21–1.13) 2.45(1.07–5.63)
P-Value 0.07 0.09 0.035
CAA-TAG Freq. 0.09 0.06 0.07 0.07 0.07 0.08
OR (95% CI) 0.75(0.40–1.40) 1.33(0.59–2.99) 1.05(0.52–2.12)
P-Value 0.37 0.50 0.89
CCG-TCG Freq. 0.02 0.03 0.04 0.04 0.03 0.06
OR (95% CI) 3.59(1.16–11.09) 1.75(0.52–5.89) 1.96(0.72–5.31)
P-Value 0.026 0.37 0.19
Controlled for age, gender and BMI. The outliers (studentized residual is greater than 2.0 or less than 22.0) were excluded. GADA, glutamic acid decarboxylase
antibodies.
doi:10.1371/journal.pone.0045573.t003
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syndrome; consequently, they were excluded from subsequent
analysis. Hence, 1107 GADA negative diabetes aged 49.5 years
(61.6% male and 38.4% female) (target group) and 620 normal
subjects without diabetes and MetS aged 51.3 years (67.6% male
and 32.4% female) (control group) were recruited in this study.
The metabolic and diabetic parameters were significantly different
between the target and control groups (Table S1).
The IGF2BP2 SNPs; rs6777038, rs16860234 and rs7651090
did not deviated from Hardy-Weinberg Equilibrium (P-val-
ue = 0.49, 0.18, 0.22 in the control group respectively). The
logistic regression model (adjusted for age, race, gender and BMI)
showed that rs6777038, rs16860234 and rs7651090 were signif-
icantly associated with GADA negative diabetes (additive,
OR=1.21; 1.36; 1.35, P= 0.03; 0.0004; 0.0002, respectively)
(Table 1). Analysis for the association of these SNPs with diabetes
among the three main Malaysian races (Malay, Chinese and
Indian) revealed that rs6777038, rs16860234 and rs7651090 were
associated with diabetes among Malaysian Chinese (Additive,
OR=1.69; 1.47; 1.39, P= 0.004; 0.02; 0.046, respectively), while
only rs16860234 showed a significant association among Malay-
sian Malay (additive, OR=1.43, P = 0.01) with diabetes. In
Malaysian Indian, the rs7651090 showed a border line association
(additive, OR=1.29, P= 0.06) with diabetes (Table 1).
Three-SNP haplotype and diplotype blocks were identified with
significant LD and constructed from the SNPs included in this
study (Figure 1). The most common haplotypes and diplotypes are
depicted in table 2 (combined races) and in table 3 (three main
Malaysian races). The haplotypes and diplotypes with frequency
,2% in total sample were excluded from subsequent analysis. The
logistic regression model (adjusted for age, race, gender and BMI)
showed that the frequency of haplotype CAA was significantly
higher in normal subjects compared to diabetic group (OR=0.67,
P = 0.001), particularly in Malay subjects (OR=0.65, P= 0.028)
(Table 2 and 3).
The haplotype TCG containing the risk alleles of the SNPs,
showed a borderline risk for diabetes in Chinese (OR=1.62,
P = 0.06). However, the haplotype CCG revealed significant
association with diabetes (OR=1.51, P= 0.01) and this risk of
association was higher in diabetic Indian (OR=2.08, P= 0.01)
subjects.
The frequency of diplotype CAA-CAA was higher in normal
subjects compared to diabetic subjects (OR=0.67, P= 0.001)
(Table 2), particularly in Malay subjects (OR=0.65, P= 0.028)
(Table 3). The diplotype CCG-TCG was a risk for diabetes
(OR=2.36, P= 0.009) and the association was higher in diabetic
Malay (OR=3.59, P = 0.026) subjects. The diplotype CAA-CCG
showed a risk for diabetic Indian (OR=2.45, P= 0.035) subjects,
whereas the other diplotypes had no significant association with
T2D.
Discussion
The association of IGF2BP2 alternative variants; rs7651090,
rs16860234 and rs6777038 with GADA negative diabetes was
evaluated in Malaysian subjects. To the best of our knowledge, this
is the first study to be performed in Southeast Asia. The strongest
association was found at rs7651090 followed by rs16860234 then
rs6777038. These SNPs showed an association in Malaysian
subjects particularly in Chinese. This is in agreement with Hu et al.
[28] who showed an association of rs7651090 with Chinese and in
disagreement with Rong et al. [30] who showed no association of
rs6777038 and rs16860234 SNPs with Pima Indians. This may be
attributed gene–gene and gene–environmental interactions that
may have contributed to many of the reported differences in gene–
disease associations between different racial or ethnic groups [33].
Another opinion attributed this to ethnic differences and linkage
disequilibrium pattern, compounded by the contribution of non-
genetic factors and lifestyle changes that can modify the risk of
T2D [20].
Several studies suggested the predominant contribution of the
IGF2BP2 variants to T2D was mediated through defects in insulin
secretion rather than action [34,35]. However, none of these SNPs
showed an association with HOMA-B or HOMA-IR (data not
shown). A similar finding was reported in a previous studies [28].
Thus, the effects of these SNPs on diabetes and metabolic
syndrome in the Asian might still need further investigations. The
haplotype (CCG) and diplotype (CCG-TCG) showed a stronger
association with GADA negative diabetes than single individual
SNPs. This prompts speculation of possible epistatic interaction
between these SNPs in determining overall risk of T2D [20]. This
study was a hospital-based and the sampling method was non-
probability thus the finding of this study limited its generalization
to whole Malaysian population. Sub-grouping of subjects accord-
ing to races resulted in small sample size particularly in Indian
subjects.
In conclusion, IGF2BP2 alternative variants were associated
with GADA negative diabetes in Malaysian subjects. The risk of
these variants was different among the three main Malaysian races
Moreover, certain IGF2BP2 haplotypes and diplotypes strengthen
the risk of diabetes.
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